Pathfinder, LLC and SyntheMed, Inc. Complete Merger - MarketWatch (press release) PDF Print
MarketWatch (press release)
In preclinical studies, PCs demonstrate the unique ability to reverse cell damage caused by diabetes, renal diseases and myocardial infarction. They may also be effective in other diseases characterized by organ-specific cellular damage.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.